Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Key Stats

• Today's Range: $36.45 to $37.52
• 50-Day Range: $28.35 to $37.41
• 52-Week Range: $23.95 to $52.34
• Volume: 2.29 million shs
• Average Volume: 1.60 million shs
• Market Capitalization: $5.95 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.59
• Consensus Rating: Moderate Buy

Ionis Pharmaceuticals Stock Analysis - MarketRank™

Ionis Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 110th out of 926 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ionis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 12 buy ratings, 5 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Ionis Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.50) to ($2.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ionis Pharmaceuticals is -12.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ionis Pharmaceuticals is -12.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ionis Pharmaceuticals has a P/B Ratio of 10.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.56% of the float of Ionis Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ionis Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Ionis Pharmaceuticals has recently decreased by 2.82%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ionis Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Ionis Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.0 / 5
• Environmental Score: -3.58

Percentage of Shares Shorted

9.56% of the float of Ionis Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ionis Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Ionis Pharmaceuticals has recently decreased by 2.82%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.56

News Sentiment

Ionis Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ionis Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

18 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 157% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Ionis Pharmaceuticals insiders have bought 2,377.19% more of their company's stock than they have sold. Specifically, they have bought $477,900.00 in company stock and sold $19,292.00 in company stock.

Percentage Held by Insiders

Only 2.60% of the stock of Ionis Pharmaceuticals is held by insiders.

Percentage Held by Institutions

93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IONS Stock Analysis - Frequently Asked Questions

How have IONS shares performed this year?

Ionis Pharmaceuticals' stock was trading at $34.96 at the start of the year. Since then, IONS shares have increased by 7.0% and is now trading at $37.41.
View the best growth stocks for 2025 here.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.14. The firm's revenue was up 10.9% on a year-over-year basis.
Read the conference call transcript.

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' top institutional shareholders include Vanguard Group Inc. (10.29%), T. Rowe Price Investment Management Inc. (10.16%), Price T Rowe Associates Inc. MD (2.05%) and BVF Inc. IL (1.20%). Insiders that own company stock include Brett P Monia, Elizabeth L Hougen, Richard S Geary, B Lynne Parshall, C Frank Bennett, Brian Birchler, Patrick R O'neil, Michael R Hayden, Eric Swayze, Eugene Schneider, Onaiza Cadoret-Manier, Joseph Baroldi, Joseph Klein III and Allene M Diaz.
View institutional ownership trends.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 6/21/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IONS
• CIK: 874015
• Web: www.ionispharma.com
• Phone: (760) 931-9200
• Fax: 760-603-2700
• Employees: 1,069
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $57.59
• High Stock Price Target: $77.00
• Low Stock Price Target: $37.00
• Potential Upside/Downside: +53.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.68
• Research Coverage: 19 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$453.90 million
• Net Margins: -63.65%
• Pretax Margin: -64.65%
• Return on Equity: -91.85%
• Return on Assets: -15.77%

Debt

• Debt-to-Equity Ratio: 2.63
• Current Ratio: 9.66
• Quick Ratio: 9.62

Sales & Book Value

• Annual Sales: $705 million
• Price / Sales: 8.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.73 per share
• Price / Book: 10.03

Miscellaneous

• Outstanding Shares: 159,160,000
• Free Float: 155,021,000
• Market Cap: $5.95 billion
• Optionable: Optionable
• Beta: 0.18